Ovarian drilling down-regulates endometrial nuclear factor-κB p65 expression in women with PCOS: A prospective case-control study.
PCOS
clomiphene
endometrial inflammation
nuclear factor κB
ovarian drilling
Journal
Turkish journal of obstetrics and gynecology
ISSN: 2149-9322
Titre abrégé: Turk J Obstet Gynecol
Pays: Turkey
ID NLM: 101656661
Informations de publication
Date de publication:
28 Mar 2022
28 Mar 2022
Historique:
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
ppublish
Résumé
To investigate the impact of laparoscopic ovarian drilling (LOD) on the expression of endometrial NFκB p65 (Rel A) in women with clomiphene-resistant polycystic ovary syndrome (PCOS). The study group comprised 25 normal-weight women with PCOS undergoing LOD and 14 control women without PCOS. Endometrial NF-κB p65 levels evaluated before and after LOD following immunohistochemical staining. The semiquantitative method was used to evaluate the intensity of NF-κB p65 levels. NF-κB p65 was found to higher in the endometrium of patients with PCOS compared to controls. LOD leads to significant down-regulation in endometrial NF-κB p65 expression. NF-κB p65 expression of PCOS and fertile control were similar after LOD. After LOD, H-score values decreased approximately 3-fold. The H-score of the control subjects was lower than the preoperative and postoperative H-score values of the control women with ovarian cyst. Expression of endometrial NF-κB p65 did not change following ovarian cystectomy. The laterality of the ovarian cyst did not cause any change in preoperative H-score values. By downregulating the endometrial NF-κB p65 expression LOD improved physiological inflammation in women with PCOS.
Identifiants
pubmed: 35343219
doi: 10.4274/tjod.galenos.2022.44845
pmc: PMC8966324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
45-50Informations de copyright
©Copyright 2022 by Turkish Society of Obstetrics and Gynecology Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Curr Opin Pharmacol. 2017 Dec;37:35-40
pubmed: 28843953
J Obstet Gynaecol. 2017 Oct;37(7):924-930
pubmed: 28617068
Reprod Sci. 2009 Feb;16(2):216-29
pubmed: 19208790
Gynecol Endocrinol. 2009 Mar;25(3):159-65
pubmed: 19347705
Immunol Rev. 2006 Apr;210:171-86
pubmed: 16623771
Eur J Contracept Reprod Health Care. 2009 Dec;14(6):437-43
pubmed: 19929647
Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2
pubmed: 21168133
J Clin Endocrinol Metab. 2011 Jun;96(6):1737-46
pubmed: 21411543
Reprod Sci. 2020 Feb;27(2):675-680
pubmed: 32046414
Fertil Steril. 2007 Feb;87(2):367-72
pubmed: 17173899
J Obstet Gynaecol Res. 2005 Apr;31(2):115-9
pubmed: 15771636
Fertil Steril. 2009 Jun;91(6):e9; author reply e10
pubmed: 19362714
Reprod Biomed Online. 2011 Jun;22(6):556-68
pubmed: 21511534
Cochrane Database Syst Rev. 2017 Nov 10;11:CD009526
pubmed: 29125183
Reprod Sci. 2013 Jul;20(7):762-70
pubmed: 23221171
Reprod Sci. 2020 Mar;27(3):787-792
pubmed: 32072606
Contraception. 2007 Jun;75(6 Suppl):S16-30
pubmed: 17531610